Kitiyodom Siraya
J Med Assoc Thai. 2016 Oct;99 Suppl 7:S133-7.
Magnesium sulfate is most effective for prevention and treatment of convulsions among preeclampsia women. The therapeutic level of magnesium at 4.8 to 8.4 mg/dL and the overdose of magnesium may be fatal. In Maharat Nakhon Ratchasima Hospital, intravenous magnesium sulfate is used with the starting dose of 4 grams followed by 1 gram per hour for symptom control. However, between 2012 and 2013, in Maharat Nakhon Ratchasima Hospital, 14 cases of eclampsia developed convulsions during magnesium sulfate therapy. Additionally, all of them had serum magnesium lower than the therapeutic level and 85.7 % of them had a body weight more than the standard (Body mass index (BMI) ≥25 kg/m(2)).
To compare the success rates of yielding the standard therapeutic level of magnesium among overweight mothers with preeclampsia after receiving 1 gram and 2 gram per hour of magnesium sulfate maintenance infusion.
This study was a randomized controlled trial study. The 38 overweight mothers (BMI ≥25 kg/m(2)) who were diagnosed as having preeclampsia and administered magnesium sulfate for prevention of convulsion were recruited. The patients who had kidney impairment or were under conservative treatment were excluded. The sample size was calculated to be 19 for each group from the pilot, with five cases per group, led to type I and type II errors, 0.05 and 0.20, respectively. They were allocated with simple randomization into an experimental group that would be treated with magnesium sulfate at 2 grams per hour and a control group treated with 1 gram per hour infusion. At the fourth hour of infusion before delivery and every four hours after delivery, the magnesium levels from both groups were compared and analyzed using Chi-square.
The body mass index of the experimental and the control groups were 33.5±6.84 and 33.7±6.09 kg/m(2), respectively. No difference in the basic characteristics between the two groups was observed. The rate of achievement of the therapeutic level of magnesium in the experimental group was higher than that of the control group both before delivery (52.6% vs. 15.8%, respectively, RR 3.3 (95% CI 1.08-10.24)) and after delivery (84.2 % vs. 42.1%, respectively, RR 2.0, 95% CI: (1.14-3.51)). Neither the overdose of magnesium nor convulsions were found in either group. The dose of magnesium in the control group was raised to 1.5 gram per hour in four patients and 2 grams per hour in seven patients to achieve the therapeutic level after delivery.
The therapeutic level of magnesium in overweight mothers with preeclampsia could be more frequently accessed before and after delivery with the dose of 2 grams per hour of magnesium sulfate infusion. No overdose of magnesium was observed. This fact would be used to improve the guideline of preeclampsia patient care.
硫酸镁对预防和治疗子痫前期女性的惊厥最为有效。镁的治疗水平为4.8至8.4毫克/分升,镁过量可能致命。在呵叻玛哈叻医院,静脉注射硫酸镁的起始剂量为4克,随后每小时1克以控制症状。然而,在2012年至2013年期间,呵叻玛哈叻医院有14例子痫前期患者在硫酸镁治疗期间发生惊厥。此外,他们所有人的血清镁均低于治疗水平,其中85.7%的人体重超过标准(体重指数(BMI)≥25千克/平方米)。
比较子痫前期超重母亲在接受每小时1克和2克硫酸镁维持输注后达到镁标准治疗水平的成功率。
本研究为随机对照试验研究。招募了38名被诊断为子痫前期并接受硫酸镁预防惊厥的超重母亲(BMI≥25千克/平方米)。排除有肾功能损害或正在接受保守治疗的患者。根据预试验,每组样本量计算为19例,每组5例导致I型和II型错误,分别为0.05和0.20。她们通过简单随机化分配到实验组,该组将接受每小时2克硫酸镁治疗,对照组接受每小时1克输注。在分娩前输注的第4小时和分娩后每4小时,使用卡方检验比较和分析两组的镁水平。
实验组和对照组的体重指数分别为33.5±6.84和33.7±6.09千克/平方米。两组基本特征未观察到差异。实验组在分娩前(分别为52.6%对15.8%,RR 3.3(95%CI 1.08 - 10.24))和分娩后(分别为84.2%对42.1%,RR 2.0,95%CI:(1.14 - 3.51))达到镁治疗水平的比率均高于对照组。两组均未发现镁过量或惊厥情况。对照组中有4名患者的镁剂量提高到每小时1.5克,7名患者提高到每小时2克以在分娩后达到治疗水平。
子痫前期超重母亲在分娩前后通过每小时输注2克硫酸镁的剂量更频繁地达到镁治疗水平。未观察到镁过量情况。这一事实将用于改进子痫前期患者护理指南。